Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

This study has been terminated.
(poor accrual)
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Cancer and Leukemia Group B
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00002772
First received: November 1, 1999
Last updated: January 22, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2004
  Primary Completion Date: February 2004 (Final data collection date for primary outcome measure)
Publications:
Bearman SI, Green S, Gralow J, et al.: SWOG/Intergroup 9623: a phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with =4 involved axillary lymph nodes. [Abstract] J Clin Oncol 23 (Suppl 16): A-572, 21s, 2005.